BOLA3-DT: A Potential Drug Target and Biomarker (G100507171)

Target Name: BOLA3-DT

NCBI ID: G100507171

BOLA3-DT

Other Name(s): BOLA3-DT variant 1 | BOLA3 divergent transcript, transcript variant 1 | BOLA3-AS1 | BOLA3 divergent transcript

BOLA3-DT: A Potential Drug Target and Biomarker

BOLA3-DT, or Brolly-associated protein 3-tetramethylammonium, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. BOLA3-DT is a member of the Brolly family of proteins, which are known for their role in various cellular processes, including cell signaling, DNA replication, and chromatin structure.

Disease-Related Characteristics

BOLA3-DT has been shown to be involved in several disease-related processes, including the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, BOLA3-DT has been shown to promote the growth and survival of cancer cells, and it has been identified as a potential drug target for various cancers, including breast, ovarian, and colorectal cancers. BOLA3-DT has also been shown to contribute to the development of resistance to chemotherapy in cancer cells.

In neurodegenerative diseases, BOLA3-DT has been linked to the progression of neurodegeneration and the development of neurofibrillary tangles. BOLA3-DT has also been shown to interact with other proteins that are involved in neurodegeneration, including tau and beta-amyloid.

In autoimmune disorders, BOLA3-DT has been linked to the development of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. BOLA3-DT has also been shown to interact with other immune cells and molecules, including T-cells and B-cells.

Potential Therapeutic Applications

The potential therapeutic applications for BOLA3-DT are vast and varied. One of the most promising potential therapeutic applications for BOLA3-DT is its potential as a cancer drug target. BOLA3-DT has been shown to promote the growth and survival of cancer cells, making it an attractive target for cancer therapies. Additionally, BOLA3-DT has been shown to contribute to the development of resistance to chemotherapy in cancer cells, making it an even more attractive target for cancer therapies.

Another potential therapeutic application for BOLA3-DT is its potential as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. BOLA3-DT has been shown to be involved in several disease-related processes, including the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. By using BOLA3-DT as a biomarker, researchers can gain insights into the underlying mechanisms of these diseases and develop new therapeutic approaches.

Conclusion

In conclusion, BOLA3-DT is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. BOLA3-DT has been shown to promote the growth and survival of cancer cells, contribute to the development of resistance to chemotherapy, and be involved in several disease-related processes. As a result, BOLA3-DT has the potential to be a valuable drug target and biomarker for various diseases. Further research is needed to fully understand the role of BOLA3-DT in disease and to develop new therapeutic approaches based on its properties.

Protein Name: BOLA3 Divergent Transcript

The "BOLA3-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BOLA3-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets